Medical Equipment

Mammalian Cell Banking Market Developments and Growth Opportunities Across 2026–2030

March 13, 2026March 16, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Much Is The Mammalian Cell Banking Market Expected To Grow In Terms Of Market Value Between 2026 And 2030?

The mammalian cell banking market size has seen rapid expansion over recent years. Projections indicate it will increase from $3.14 billion in 2025 to $3.5 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.3%. Historically, this growth has been driven by monoclonal antibody development, increased vaccine manufacturing, regulatory quality requirements, academic research expansion, and biologics commercialization.

The mammalian cell banking market is anticipated to experience significant expansion in the coming years. This market is projected to reach $5.31 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 11.0%. This projected growth is driven by factors such as advancements in gene therapy, the expansion of personalized medicine, the development of biosimilars, robust cell-based therapy pipelines, and the necessity for long-term cell traceability. Key trends anticipated during this period encompass the standardization of cell line preservation methods, an increase in biopharmaceutical pipelines, the expansion of CGMP-compliant cell banking facilities, a heightened emphasis on genetic stability, and a growing reliance on specialized outsourcing facilities.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28262&type=smp

What Key Drivers Are Influencing The Growth Of The Mammalian Cell Banking Market?

The increasing demand for cell-based therapies is projected to drive the growth of the mammalian cell banking market in the future. Cell-based therapies are advanced medical treatments that employ living cells, frequently modified or engineered, to mend, substitute, or restore damaged tissues and organs, providing focused remedies for a wide array of conditions. The need for cell-based therapies is growing because the rising prevalence of chronic and rare diseases creates an urgent requirement for more effective and precise treatment options. Mammalian cell banking supports cell-based therapies by offering a reliable, standardized supply of high-quality cells, guaranteeing consistency, safety, and scalability in the development and production of regenerative treatments. For example, in April 2024, the American Society of Gene and Cell Therapy, a US-based non-profit medical and scientific organization, indicated that the total number of therapies across all clinical pipeline phases has expanded since the end of 2023, with Phase I showing the strongest increase of 11% since before the fourth quarter of 2022. Thus, the escalating demand for cell-based therapies is propelling the growth of the mammalian cell banking market.

What Major Segment Divisions Exist Within The Mammalian Cell Banking Market?

The mammalian cell banking market covered in this report is segmented –

1) By Product Type: Master Cell Bank, Working Cell Bank

2) By Cell Type: Chinese Hamster Ovary Mammalian Cell Banking (CHO), Baby Hamster Kidney (BHK), Non-Secreting 0 (NS0), YB2/0 And P2/0, Human Embryonic Kidney 293 (HEK293) And Derivatives, Henrietta Lacks (HELA)

3) By Storage Type: Liquid Nitrogen, Controlled Rate Freezer, Flash Freezing

4) By Application: Drug Development, Vaccine Production, Gene Therapy, Monoclonal Antibody Production

5) By End User: Academic And Research Laboratories, Biopharmaceutical Companies, Contract Research Organizations (CROs)

Subsegments:

1) By Master Cell Bank: Recombinant Cell Lines, Hybridoma Cell Lines, Primary Cell Lines, Genetically Engineered Cell Lines, Viral Vector Producing Cell Lines

2) By Working Cell Bank: Current Good Manufacturing Practice (CGMP)-Compliant Cell Banks, Research-Grade Cell Banks, Clinical Trial Cell Banks, Commercial Production Cell Banks, Stability Testing Cell Banks

How Are Trends Shaping The Direction Of The Mammalian Cell Banking Market?

Leading firms in the mammalian cell banking market are concentrating their efforts on creating advanced solutions, including novel stable cell line systems, with the aim of boosting cell line efficiency, maintaining prolonged genetic stability, and simplifying biopharmaceutical manufacturing operations. These stable cell line systems consist of mammalian cells that have been genetically engineered to reliably generate a specific protein or therapeutic substance across many generations, exhibiting significant genetic stability and consistent outcomes. As an illustration, in August 2024, WuXi Biologics, a biopharmaceutical firm from China, introduced the WuXia293 Stable platform. This is an inventive HEK293-based stable cell line system tailored for the creation and production of biological molecules that are challenging to express. Leveraging its proprietary mammalian cell line development technology, this platform guarantees steady expression and uniform quality through extended cell passages. The WuXia293 Stable platform addresses difficulties such as low yields and diminished quality typically encountered with conventional CHO cell systems. It achieves this by providing high protein concentrations, enhanced human-like glycosylation, and scalable production suitable for both clinical and commercial manufacturing.

Which Companies Are Leading Innovation In The Mammalian Cell Banking Market?

Major companies operating in the mammalian cell banking market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Eurofins Scientific SE, Charles River Laboratories International Inc., Catalent Inc., Sartorius Stedim Biotech S A, Samsung Biologics Co Ltd, CMIC Holdings Co Ltd, WuXi Biologics Inc., Evotec SE, AGC Biologics Inc., GenScript ProBio Co Ltd, Syngene International Limited, KBI Biopharma Inc., Rentschler Biopharma SE, Polpharma Biologics S A, Abzena plc, 53Biologics, Cellistic, GBI Biomanufacturing, ABL Inc, OmniaBio, uBriGene Biosciences

Read the full mammalian cell banking market report here:

https://www.thebusinessresearchcompany.com/report/mammalian-cell-banking-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Mammalian Cell Banking Market?

North America was the largest region in the mammalian cell banking market in 2025. The regions covered in the mammalian cell banking market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Mammalian Cell Banking Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28262&type=smp

Browse Through More Reports Similar to the Global Mammalian Cell Banking Market 2026, By The Business Research Company

Cell Cultures Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-cultures-global-market-report

Cell Harvesting Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-harvesting-global-market-report

Cell Based Assays Market Report 2026

https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795